Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation

Therapeutics and Clinical Risk Management

Volumn 12, Issue , 2016, Pages 527-533

  Yan, Panshi ^a   Qian, Cheng ^a   Wang, Wenzhan ^a   Dong, Yi ^a   Wan, Guangming ^a   Chen, Yue ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Diabetic macular edema; Photocoagulation; Ranibizumab; Vitreous body

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETREATMENT; SUBCONJUNCTIVAL HEMORRHAGE; THROMBOEMBOLISM; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 84962702443     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S99224     Document Type: Article

References (20)

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564.
2. Perente I, Alkin Z, Ozkaya A, et al. Focal laser photocoagulation in non-center involved diabetic macular edema. Med Hypothesis Discov Innov Ophthalmol. 2014;3(1):9–16.
3. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513–518.
4. Luo XR, Zheng QX, Li WS. Progress of evidence-based medicine study of central retinal vein occlusion. Chin J Pract Ophthalmol. 2011;29(2):103–109.
5. Rii T, Itoh Y, Inoue M, Hirakata A. Foveal cone outer segment tips line and disruption artifacts in spectral-domain optical coherence tomographic images of normal eyes. Am J Ophthalmol. 2012;153:524–529.
6. Zheng Z. Prevention and treatment of diabetic retinopathy: progress, challenges, and future prospects. Chin J Ocul Fundus Dis. 2012;28(3):209–214.
7. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: Rise and Ride. Ophthalmology. 2012;119(4):789–801.
8. Titchenell PM, Antonetti DA. Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy. Diabetes. 2013;62(6):1808–1815.
9. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranbizumab therapy for diabetic macular edema: the 36-month results from two phase III trials RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
10. Hua W, Cao S, Cui J, Maberley D, Matsubara J. Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy. Can J Ophthalmol. 2013;48(2):88–92.
11. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol. 2013;7:1257–1267.
12. Srinivasan VJ, Monson BK, Wojtkowski M, et al. Characterization of outer retinal morphology with high-speed, ultrahigh-resolution optical coher­ence tomography. Invest Ophthalmol Vis Sci. 2008;49(4):1571–1580.
13. Ai H, Yang XG. Expression of VEGF and IL-6 in atria and vitreous cavity of patients with central retinal vein occlusion macular edema. Chin J Cell Mol Immunol. 2011;27:1124–1126.
14. Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics. 2009;64(2):16–20.
15. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):915–930.
16. Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131(2):139–145.
17. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-related rat model. Arch Ophthalmol. 2001;119(2):399–340.
18. Benhamou N, Massia P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003;135:246–249.
19. Lima VC, Yeung L, Castro LC, Landa G, Rosen RB. Correlation between spectral domain optical coherence tomography findings and visual out-comes in central retinal vein occlusion. Clin Ophthalmol. 2011;5:299–305.
20. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The restore study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625.